Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype

Oncogene

Volumn 31, Issue 6, 2012, Pages 671-682

  Jiang, J ^a   Zhang, Y ^a,a   Chuai, S ^a   Wang, Z ^a   Zheng, D ^a   Xu, F ^a   Li, C ^a   Liang, Y ^a   Chen, Z ^a  

^a Novartis Institutes for Biomedical Research   (China)

Author keywords

cancer stem cells; CD90; ERBB2; gastric cancer; trastuzumab (herceptin)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; THY 1 ANTIGEN; TRASTUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; FEMALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, THY-1; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; LEUCOVORIN; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; ORGANOPLATINUM COMPOUNDS; PHENOTYPE; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPHEROIDS, CELLULAR; STOMACH NEOPLASMS; TUMOR BURDEN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856963775     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.282     Document Type: Article

References (72)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988. (Pubitemid 36418143)
2. Araki H, Yoshinaga K, Boccuni P, Zhao Y, Hoffman R, Mahmud N. (2007). Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. Blood 109: 3570-3578. (Pubitemid 46572552)
3. Bernstein ID, Tam MR, Nowinski RC. (1980). Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen. Science 207: 68-71. (Pubitemid 10142300)
4. Beuzeboc P, Scholl S, Garau XS, Vincent-Salomon A, Cremoux PD, Couturier J et al. (1999). Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene? Bull Cancer 86: 544-549.
5. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP et al. (2010). Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466: 133-137.
6. Bowles MJ, Benjamin IS. (2001). ABC of the upper gastrointestinal tract: cancer of the stomach and pancreas. BMJ 323: 1413-1416. (Pubitemid 33152497)
7. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM et al. (2001). Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722-2730. (Pubitemid 32441378)
8. Chen W, Wang GM, Liu YJ, Qian RZ. (2007). Cancer stem-like cells in human prostate carcinoma cells DU145: The seeds of the cell line? Cancer Biol Ther 6: 763-768.
9. Cho RW, Wang X, Diehn M, Shedden K, Chen GY, Sherlock G et al. (2008). Isolation and molecular characterization of cancer stem cells in MMTV-oI4Wnt-1o/I4 murine breast tumors. Stem Cells 26: 364-371. (Pubitemid 351413596)
10. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL et al. (2006). Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66: 9339-9344. (Pubitemid 44623625)
11. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951. (Pubitemid 41713363)
12. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A et al. (2009). Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106: 13820-13825.
13. Dalerba P, Dylla SJ, Park I-K, Liu R, Wang X, Cho RW et al. (2007). Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104: 10158-10163. (Pubitemid 47175279)
14. Dan YY, Riehle KJ, Lazaro C, Teoh N, Haque J, Campbell JS et al. (2006). Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci USA 103: 9912-9917. (Pubitemid 43993597)
15. Dennis JE, Esterly K, Awadallah A, Parrish CR, Poynter GM, Goltry KL. (2007). Clinical-scale expansion of a mixed population of bone marrow-derived stem and progenitor cells for potential use in bone tissue regeneration. Stem Cells 25: 2575-2582. (Pubitemid 47582750)
16. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. (2003). In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270. (Pubitemid 36583168)
17. Dontu G, Jackson K, McNicholas E, Kawamura M, Abdallah W, Wicha M. (2004). Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 6: R605-R615.
18. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira S-M, Garca-Echeverra C et al. (2009). The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 106: 268-273.
19. Euhus D, Hudd C, LaRegina M, Johnson F. (1986). Tumor measurement in the nude mouse. J Surg Oncol 31: 229-234. (Pubitemid 16104025)
20. Farnie G, Clarke R. (2007). Mammary stem cells and breast cancer-role of notch signalling. Stem Cell Rev Rep 3: 169-175. (Pubitemid 350129719)
21. Fukuda K, Saikawa Y, Ohashi M, Kumagai K, Kitajima M, Okano H. (2009). Tumor initiating potential of side population cells in human gastric cancer. Int J Oncol 34: 1201-1207.
22. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cancer Cell 1: 555-567. (Pubitemid 350056407)
23. Haack-Sorensen M, Friis T, Bindslev L, Mortensen S, Johnsen H, Kastrup J. (2007). Comparison of different culture conditions for human mesenchymal stromal cells for clinical stem cell therapy. Scan J Clin Lab Invest 12: 1-17.
24. Herrera MB, Bruno S, Buttiglieri S, Tetta C, Gatti S, Deregibus MC et al. (2006). Isolation and characterization of a stem cell population from adult human liver. Stem Cells 24: 2840-2850. (Pubitemid 46053020)
25. Jamieson CHM, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. (2004). Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351: 657-667. (Pubitemid 39063268)
26. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. (2008). Cancer statistics, 2008. CA Cancer J Clin 58: 71-96. (Pubitemid 351521864)
27. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L et al. (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7: 330-338.
28. Kauraniemi P, Hautaniemi S, Autio R, Astola J, Monni O, Elkahloun A et al. (2003). Effects of herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene 23: 1010-1013.
29. Kelly LM, Gilliland DG. (2002). Genetics of myeloid leukemias. Annu Rev Genom Hum Genet 3: 179-198. (Pubitemid 35217435)
30. Kondo T, Setoguchi T, Taga T. (2004). Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101: 781-786. (Pubitemid 38121035)
31. Korkaya H, Paulson A, Iovino F, Wicha MS. (2008). HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27: 6120-6130.
32. Lazaro CA, Croager EJ, Mitchell C, Campbell JS, Yu C, Foraker J et al. (2003) Establishment, characterization, and long-term maintenance of cultures of human fetal hepatocytes. Hepatology 38: 1095-1106. (Pubitemid 37314818)
33. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V et al. (2007). Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037.
34. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu M-F et al. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679.
35. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir I et al. (2006). Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67.
36. Lobo NA, Shimono Y, Qian D, Clarke MF. (2007). The biology of cancer stem cells. Annu Rev Cell Dev Biol 23: 675-699.
37. Ma S, Chan KW, Hu L, Lee TKW, Wo JYH, Ng IOL et al. (2007). Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556. (Pubitemid 46890873)
38. Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K et al. (2007). Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 1: 55-70.
39. Marx AH, Tharun L, Muth J, Dancau A-M, Simon R, Yekebas E et al. (2009). HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 40: 769-777.
40. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y et al. (2004). Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-2336. (Pubitemid 38326254)
41. Nakamura Y, Muguruma Y, Yahata T, Miyatake H, Sakai D, Mochida J et al. (2006). Expression of CD90 on keratinocyte stem/progenitor cells. Br J Dermatol 154: 1062-1070. (Pubitemid 43727386)
42. O'Brien CA, Pollett A, Gallinger S, Dick JE. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110. (Pubitemid 46067310)
43. Oikonomou D, Hassan K, Kaifi J, Fiegel H, Schurr P, Reichelt U et al. (2007). Thy-1 as a potential novel diagnostic marker for gastrointestinal stromal tumors. J Cancer Res Clin Oncol 133: 951-955. (Pubitemid 47561711)
44. Okita K, Ichisaka T, Yamanaka S. (2007). Generation of germlinecompetent induced pluripotent stem cells. Nature 448: 313-317. (Pubitemid 47080336)
45. Paik S, Kim C, Wolmark N. (2008). HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358: 1409-1411. (Pubitemid 351468442)
46. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P et al. (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973-978. (Pubitemid 46154721)
47. Qiang L, Yang Y, Ma Y-J, Chen F-H, Zhang L-B, Liu W et al. (2009). Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 279: 13-21.
48. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. (2008). Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
49. Rege TA, Hagood JS. (2006). Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J 20: 1045-1054. (Pubitemid 44943900)
50. Reya T, Clevers H. (2005). Wnt signalling in stem cells and cancer. Nature 434: 843-850. (Pubitemid 40558990)
51. Reya T, Morrison SJ, Clarke MF, Weissman IL. (2001). Stem cells, cancer, and cancer stem cells. Nature 414: 105-111. (Pubitemid 33041634)
52. Reynolds B, Weiss S. (1992). Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255: 1707-1710.
53. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115. (Pubitemid 46067311)
54. Riley L, Zhou H, Lange K, Sinsheimer JS, Sehl ME.(2010). Breast cancer stem cell extinction models: implications for HER2 targeted therapy. AACR 2010 Meeting, abstract 104.
55. Ruangpratheep C, Lohachittranond C, Poonpracha T, Punyarit P. (2005). OCT4 expression on a case of poorly differentiated (insular) carcinoma of the thyroid gland and minireview. J Med Assoc Thai 88: S281-S289.
56. Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y. (2006). Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 32: 164-170; 110.1097/1001.mpa. 0000202947.0000280117.a0000202940.
57. Seeger RC, Danon YL, Rayner SA, Hoover F. (1982). Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody. J Immunol 128: 983-989. (Pubitemid 12168475)
58. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396-401. (Pubitemid 39551674)
59. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712. (Pubitemid 19147683)
60. Spisek R, Kukreja A, Chen L-C, Matthews P, Mazumder A, Vesole D et al. (2007). Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 204: 831-840. (Pubitemid 46631612)
61. Taipale J, Beachy PA. (2001). The Hedgehog and Wnt signalling pathways in cancer. Nature 411: 349-354. (Pubitemid 32467044)
62. Takahashi K, Yamanaka S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676. (Pubitemid 44233629)
63. Takaishi S, Okumura T, Wang TC. (2008). Gastric cancer stem cells. J Clin Oncol 26: 2876-2882.
64. Tanner M, Hollme?n M, Junttila TT, Kapanen AI, Tommola S, Soini Y et al. (2005). Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278. (Pubitemid 40309309)
65. Tomayko M, Reynolds C. (1989). Determination of subcutaneous tumor size in athymic (nude) mice, Cancer Chemother. Pharmacol 24: 148-154. (Pubitemid 19163397)
66. Wang K-H, Kao A-P, Chang C-C, Lee J-N, Hou M-F, Long C-Y et al. (2010). Increasing CD44 +CD24-tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. Mol Cancer 9: 288.
67. Wang Q, He W, Lu C, Wang Z, Wang J, Giercksky KE et al. (2009). Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res 29: 1233-1241.
68. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K et al. (2007). In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448: 318-324. (Pubitemid 47080337)
69. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P et al. (2008). Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13: 153-166. (Pubitemid 351163165)
70. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M et al. (2006). Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15: 65-71.
71. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J et al. (2009). Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458: 776-779.
72. Zou G-M. (2008). Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver. J Cell Physiol 217: 598-604.